A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
OBJECTIVE
The purpose of this study was to examine the effects of of bromocriptin combined with clomiphene citrate in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.


METHODS
Prospective, double-blind, controlled study.


METHODS
University teaching hospital.


METHODS
One hundred polycystic ovary patients and normal prolactin (PRL) who were clomiphene citrate resistant.


METHODS
Treatment group received 150 mg clomiphene citrate on days 5-9 and 7.5 mg bromocriptin continuously. Control group received the same protocol of clomiphene citrate combined with placebo.


METHODS
Hormonal status, follicular monitoring, ovulation rate.


RESULTS
Follicular development (follicular size greater than 15 mm) was observed in 12 (25.5%) and eight (15.1%) women in treatment and placebo group respectively ( P=0.29). The serum prolactin level was within normal limits in all patients before treatment. After 3 and 6 months of treatment with bromocriptin, there was a significant decrease in serum level of prolactin ( P=0.000001). No any significant differences was seen in ovulation, and serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEAS), progesterone (P) between treatment and placebo group after treatment.


CONCLUSIONS
The only significant effect of long-term bromocriptin therapy in clomiphene citrate resistant polycystic ovary women was to lower the serum prolactin concentration. It was also concluded that 10-15% of patients with polycystic ovaries experienced occasional ovulatory cycles and pregnancy whether or not they were on treatment.
Parsanezhad
Mohammad Ebrahim
ME
Department of Obstetrics and Gynecology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran. parsame@sums.ac.ir
Alborzi
Saeed
S
Namavar Jahromi
Bahia
B
D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage*; D002996:Clomiphene / Q000008:administration & dosage; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D005299:Fertility Agents / Q000008:administration & dosage*; D006801:Humans; D010060:Ovulation / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011388:Prolactin / Q000097:blood*; D011446:Prospective Studies; D016896:Treatment Outcome
D005299:Fertility Agents; D002996:Clomiphene; D001971:Bromocriptine; D011388:Prolactin